SINTX Technologies, Inc. received written notification from Nasdaq confirming it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1). Based on its Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, the company satisfied the $2.5 million threshold. Nasdaq determined that the previously disclosed deficiency matter is now closed. SINTX Technologies operates in the advanced ceramics industry, developing and commercializing silicon nitride biomaterials and medical devices.

SINTX Technologies provided a mid-year business update for the period ended June 30, 2026. The company raised approximately $5.0 million in gross proceeds through private placement and ATM sales during Q2. It received roughly $3.2 million in new industrial purchase orders with revenue recognition expected starting in Q3 2026. Management issued revenue guidance of $900,000 to $1.1 million for Q3 and $1.0 million to $1.3 million for Q4 2026. The company advanced commercialization of its FDA-cleared SiNAPTIC Foot & Ankle Implant System via a Limited Use Release and established a distributor network. Additionally, SINTX completed construction of an advanced 3D printing facility and secured an extension on NIH grant funding. SINTX Technologies operates in the advanced ceramics industry, developing silicon nitride biomaterials and medical devices for orthopedic applications.

SINTX Technologies, Inc. has engaged Southern Metrics Consulting to establish a Strategic Opportunity Management Program to identify, evaluate, and pursue strategic opportunities such as commercial partnerships, licensing, joint ventures, and acquisitions to enhance stockholder value. The program is led by board member Chris Lyons, who serves as CEO of Southern Metrics. SINTX Technologies, Inc. is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials and medical devices for medical and industrial applications.

Sintx Technologies, Inc. entered into a letter agreement with MedTech Ceramics, LP to restructure a previous warrant inducement transaction from September 2025. The agreement involves issuing 255,267 shares of common stock from abeyance and replacing the remaining 251,987 abeyance shares with a pre-funded warrant, while also replacing an existing warrant with a new warrant to purchase 1,268,135 shares at $2.14 per share. Sintx Technologies, Inc. operates in the medical technology industry, providing advanced ceramic materials for medical applications.

SINTX Technologies, Inc. entered into a Securities Purchase Agreement on June 2, 2026, to conduct a private placement of 1,882,845 units at $2.39 per unit for approximately $4.5 million in gross proceeds. Each unit includes one share of common stock and two warrants, a Class A and a Class B warrant, both featuring an exercise price of $2.14 per share.